Neoplasms

All Conditions

Carcinoma

Carcinoma, Basal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Basal Cell

All Drugs and Chemicals

Dimethyl Sulfoxide

Eidi Christensen, MD

The purpose of this study is to registrate long time clinical and histological treatment response of basal cell carcinoma (BCC) lesions treated with one or two procedures of dimethylsulfoxide supported 5-aminolaevulinic acid photodynamic therapy (DMSO-PDT).

DMSO-PDT of BCC - A 6 Year Follow up

Dimethylsulphoxide-supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curettage - A 6 Year Clinical and Histological Evaluation.

St. Olavs Hospital

Norwegian University of Science and Technology

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Leukemia

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Hematologic Neoplasms

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Lymphosarcoma

Protective Agents

Antioxidants

Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.

Cryopreservation of HSCs using 5% DMSO concentration

Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.

Cryopreservation of HSCs using 7,5% DMSO concentration

Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.

Cryopreservation of HSCs using 10% DMSO concentration

The main aim of the study was to evaluate the clinical impact of different DMSO concentrations in cryopreservation mixture (5%, 7.5%, 10%) on reconstitution of hematopoiesis after autologous hematopoietic stem cell transplantation.

The procedure of autologous hematopoietic stem cell (HSC) transplantation requires cryopreservation of HSCs. Addition of DMSO (dimethyl sulfoxide) is necessary to secure the viability of such cells, but this cryoprotectant is potentially toxic to stem cell recipient. The concentrations of DMSO in cryopreservation mixture vary strongly between protocols in different transplant centers. Usually, the HSCs are stored in mixtures containing 10% DMSO, but there is no sufficient evidence that this concentration of DMSO is indeed optimal.

The main aim of the study is to evaluate the clinical impact of reduction of DMSO concentration in cryopreservation mixture on engraftment after autologous hematopoietic stem cell transplantation. 150 consecutive patients will be randomly assigned to one of three study arms (50 patients each). HSCs obtained by leukapheresis will be cryopreserved in three concentrations of DMSO: 5%, 7.5%, 10%, respectively. Evaluation of the mixtures will be carried out by monitoring reconstitution of hematopoiesis and the frequency the side effects in patients. The most important aspect of our evaluation will be the speed of neutrophil recovery after transplantation (defined by the first day, when absolute neutrophil count in peripheral blood will be higher than 0.5 G/L). The investigators will also evaluate the toxicity of cell suspension by monitoring the frequency of infusion-related adverse events (like nausea or vomiting) during infusion and 24 hours after transplantation.

Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.

Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells.

Maria Sklodowska-Curie National Research Institute of Oncology

Prof., MD

Symptoms and General Pathology

Syndrome

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Hodgkin Disease

Primary Myelofibrosis

Lymphoma, Non-Hodgkin

Lymphatic Diseases

Bone Marrow Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Myeloproliferative Disorders

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Hodgkin Lymphoma

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

Antineoplastic Agents

Antirheumatic Agents

Anti-Infective Agents

Dermatologic Agents

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Melphalan

Cyclosporine

Cyclosporins

Lenograstim

Mycophenolic Acid

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antimetabolites

Enzyme Inhibitors

Clotrimazole

Miconazole

Antifungal Agents

Calcineurin Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Antitubercular Agents

REDUCED INTENSITY CONDITIONING (RIC):

Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.

Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.

GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.

TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0.

All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6

cyclophosphamide

Given by IV during prep at 40mg/m2 for 5 days

fludarabine phosphate

Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1

total-body irradiation

Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100

cyclosporine

Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.

mycophenolate mofetil

Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.

umbilical cord blood transplantation

The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).

mesenchymal stem cell transplantation

Leland Metheny, MD

This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil at the time of transplant may stop this from happening.

PRIMARY OBJECTIVES:

I. To estimate the feasibility of combining intra-osseous umbilical cord blood (UCB) hematopoietic stem cells and human mesenchymal stromal cells (hMSC) following reduced intensity conditioning (RIC).

SECONDARY OBJECTIVES:

I. To estimate the time to engraftment of intra-osseous (IO) UCB transplant combined with hMSC following RIC.

II. To estimate the safety profile of IO UBC transplant combined with hMSC.

OUTLINE:

REDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide intravenously (IV) over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total body irradiation (TBI) on day -1.

GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine orally (PO) or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO twice daily (BID) on days -5 to 100.

TRANSPLANT: Patients undergo intra-osseous UCB and hMSC co-transplant on day 0.

After completion of study treatment, patients are followed up at days 28 and 100, and then at 6, 9, and 12 months.

Intra-Osseous Co-Transplant of UCB and hMSC

Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study

Primary graft failure is defined by \<10% BM cellularity in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment

Primary graft failure is defined by \<500 ANC cell/ul in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment

Primary graft failure is defined by hematopoietic recovery with \<10% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment

Primary graft failure is defined by hematopoietic recovery with \<40% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment

The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.

The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.

The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier.

The median time of platelet recovery will be estimated using the methods of Kaplan and Meier.

National Cancer Institute (NCI)

Case Comprehensive Cancer Center

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
DMSO-PDT of BCC - A 6 Year Follow up	NCT00218829	Carcinoma, Basa...		18 Years -	Norwegian University of Science and Technology
Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.	NCT02452099	Multiple Myelom... Lymphomas Leukemias	Cryopreservatio... Cryopreservatio... Cryopreservatio...	18 Years -	Maria Sklodowska-Curie National Research Institute of Oncology
DMSO-PDT of BCC - A 6 Year Follow up	NCT00218829	Carcinoma, Basa...		18 Years -	Norwegian University of Science and Technology
Intra-Osseous Co-Transplant of UCB and hMSC	NCT02181478	Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Myelofibrosis Relapsed Non-Ho... Refractory Non-... Hodgkin Lymphom... Refractory Hodg... Relapsed Chroni... Refractory Chro... Lymphoid Malign... Chronic Myeloge...	cyclophosphamid... fludarabine pho... total-body irra... cyclosporine mycophenolate m... umbilical cord ... mesenchymal ste...	18 Years - 75 Years	Case Comprehensive Cancer Center

Spots Global Cancer Trial Database for dmso

Every month we try and update this database with for dmso cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dmso

Every month we try and update this database with for dmso cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dmso cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.